These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An extended dosing regimen of epoetin alfa 60,000 units every 2 weeks in anemic patients with cancer receiving chemotherapy.
    Author: Gregory SA, Xie J, Szczudlo T, Williams D, Woodman RC, Wilhelm FE.
    Journal: Support Cancer Ther; 2007 Sep 01; 4(4):225-32. PubMed ID: 18632521.
    Abstract:
    PURPOSE: This open-label study evaluated the safety and efficacy of epoetin alfa 60,000 U once weekly Initialsly followed by 60,000 U every 2 weeks in anemic patients with cancer receiving chemotherapy. PATIENTS AND METHODS: Patients receiving weekly or every- 4-weeks chemotherapy regimens for nonmyeloid malignancy and with hemoglobin (Hb) level </= 11 g/dL were enrolled. They received epoetin alfa 60,000 U weekly during the Initials dosing phase (IDP) to a target Hb level of 12 g/dL. Patients who did not exhibit target Hb level within 12 weeks were withdrawn. Patients who had a hemogloblin level of 12 g/dL during the IDP entered the extended dosing phase (EDP), where epoetin alfa 60,000 U was administered every 2 weeks. Total maximum study duration was 24 weeks. RESULTS: A total of 129 patients (mean baseline Hb level, 10 g/dL) were enrolled and received >/= 1 dose of epoetin alfa. Sixty-eight percent of patients had hematopoietic response (Hb increase >/= 2 g/dL from baseline or Hb level >/= 12 g/dL during the IDP; primary endpoint). Eighty-four patients entered the EDP; 74 of 84 patients (88%) maintained average Hb level between 11 g/dL and 13 g/dL up to time of withdrawal or study completion. Adverse events were consistent with the underlying disease process and chemotherapy treatment. Six patients (4.7%) in the IDP and 8 patients (9.5%) in the EDP experienced clinically relevant thrombotic vascular events. CONCLUSION: In this study, approximately 90% of patients receiving an extended dosing regimen of epoetin alfa 60,000 U every 2 weeks were able to maintain Hb level between 11 g/dL and 13 g/dL.
    [Abstract] [Full Text] [Related] [New Search]